Form 4: Immunome Inc. Executive Acquires 210,000 Stock Options
SEC Filing
Sandra G. Stoneman, Chief Legal Officer & GC of Immunome Inc., acquired 210,000 stock options on August 9, 2024.
Summary
- Sandra G. Stoneman, the Chief Legal Officer & GC of Immunome Inc., filed a Form 4 on August 13, 2024, reporting a transaction.
- On August 9, 2024, Stoneman acquired 210,000 stock options with an exercise price of $12.92.
- These options vest over time, with 25% vesting on August 9, 2025, and the remainder vesting monthly over the following three years.
- The options expire on August 8, 2034.
Sentiment
Score: 6
Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it reflects an executive's increased stake in the company.
Positives
- The acquisition of stock options by a key executive could signal confidence in the company's future prospects.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Option grants are a common form of executive compensation in the biotechnology industry.
Stakeholder Impact
- The acquisition of stock options by a key executive could be viewed positively by shareholders.
Key Dates
| Date | Description |
|---|---|
| 08/09/2024 | Date of transaction: Sandra Stoneman acquired 210,000 stock options. |
| 08/09/2025 | 25% of the acquired stock options vest. |
| 08/08/2034 | Expiration date of the stock options. |
| 08/13/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.